Targovax ASA: circRNA poster to be presented at the AACR Annual Meeting

15 Mar 2023 13:43 CET

Oslo, Norway, 15 March 2023 - Targovax ASA (OSE: TRVX) today announces that an
abstract describing its circular RNA platform has been accepted for poster
presentation at the 2023 American Association for Cancer Research (AACR) Annual
Meeting in Orlando, USA.

The abstract describes the advantage of protein expression utilizing
Targovax´proprietary circAde vector system. By comparing protein expression from
circRNA and mRNA-based vectors, it is shown that the circAde-system out-performs
conventional mRNA-based designs, both in terms of protein expression level and
durability. Persistent and prolonged protein expression in patients correlate
with positive treatment outcome. The results thus highlight the circAde
platform's potential for development of novel, more effective medicines for the
treatment of cancer and other diseases.

The abstract has been released on the AACR website
(https://www.abstractsonline.com/pp8/#!/10828/presentation/5271). The poster is
scheduled for presentation Tuesday 18 April 2022 and will be available on
Targovax's website (https://www.targovax.com/en/oncos-oncolytic-virus
-publications-posters-and-oral-presentations/) after the presentation.

Poster circAde: a circRNA-based system for prolonged
title: and more effective treatment of cancer
Date and Tuesday 18 April 2023, 13:30- 17:00 CDT /
time: 20:30-24:00 CET
Location: Orange County Convention Center, Orlando,
Florida
Session High-throughput Screening, Lead Identification
title: and Optimization, and in Silico Drug Discovery
Poster 5335 / 17
number:
Presenter: Thomas Birkballe Hansen, VP Research, Targovax

About AACR

The AACR Annual Meeting is the focal point of the cancer research community,
where scientists, clinicians, other health care professionals, survivors,
patients, and advocates gather to share the latest advances in cancer science
and medicine. From population science and prevention; to cancer biology,
translational, and clinical studies; to survivorship and advocacy; the AACR
Annual Meeting highlights the work of the best minds in cancer research from
institutions all over the world.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax's focus is to
activate the patient's immune system to fight cancer, and to bring benefit to
cancer patients with few available treatment alternatives. Targovax is
developing its product candidates in different cancer indications, including
melanoma, mesothelioma, multiple myeloma and pancreatic cancer.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system against the tumor. ONCOS-102 has
demonstrated a favorable efficacy, immunological and safety profile in several
indications, both as monotherapy and in combinations, and ONCOS-102 is
progressing into a randomized phase 2 trial in melanoma patients resistant to PD
-1 checkpoint inhibitor treatment.

Targovax has also established a cutting-edge circular RNA (circRNA) program with
the intent to develop next generation RNA therapeutics for various applications,
building on clinical experience and deep mechanistic insights from its first
generation products.  In addition, Targovax has a KRAS immunotherapy program,
with lead candidate TG01 due to enter clinical trials in an enhanced format in
pancreatic cancer and multiple myeloma during early 2023. This provides Targovax
with a rich pipeline of innovative future therapeutic candidates to follow ONCOS
-102.

More information:
Access the news on Oslo Bors NewsWeb site